Leerink Partners analyst Andrew Berens maintained a Buy rating on Astrazeneca Plc (LON:AZN) on Thursday, setting a price target of $73, which is approximately 24.15% above the present share price of $58.8.
Berens expects Astrazeneca Plc to post earnings per share (EPS) of $0.42 for the fourth quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in AstraZeneca (NASDAQ:AZN), with an average price target of $73.
The analysts price targets range from a high of $73 to a low of $73.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $8.22 billion and a net profit of $1.13 billion. The company's market cap is $182.18 billion.
According to TipRanks.com, Leerink Partners analyst Andrew Berens is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 5.2% and a 58.85% success rate.
Founded in 1992, UK-based AstraZeneca Plc is a leading global pharmaceutical company, which is engaged in delivering life-changing medicines. The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases.